An upcoming study will evaluate the efficacy and safety profile of a chemotherapeutic regimen named R-CMOP for patients with diffuse large B-cell lymphoma (DLBCL).

Researchers will soon initiate the recruiting process for this multicenter, open-label, interventional study. The clinical trial will include approximately 30 participants previously diagnosed with DLBCL.

Read more about DLBCL therapies

The individuals will receive a chemotherapeutic scheme that consists of rituximab (375 mg/m2), mitoxantrone hydrochloride liposome (18 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2) or vindesine (3 mg/m2), and prednisone (60 mg/m2). Up to 6 cycles will be administered, with each cycle lasting 21 days.

The authors aim to measure the objective response rate after up to 6 chemotherapeutic cycles with R-CMOP as the primary outcome.

The secondary outcomes will include the complete remission rate and duration of remission after up to 6 cycles, as well as the progression-free survival and overall survival rates after 1 year. Moreover, the study will also observe and record any adverse events that occur from day 1 of the treatment to day 28 after the last dose to determine the safety profile of this therapeutic combination in patients with DLBCL.

Patients aged 18 to 80 years with a confirmed diagnosis of DLBCL by histopathological examination and an expected survival of 3 months or more are eligible for the study. Participants must also have at least 1 evident lesion described in the Lugano 2014 criteria, such as a lymph node lesion with a diameter greater than 1.5 cm or an extrinsic non-lymph node lesion measuring over 1 cm in diameter.

This novel research, titled “R-CMOP in patients with primary diffuse large B-cell lymphoma,” is expected to start in March 2023 and be completed by August 2024.


R-CMOP in patients with primary diffuse large B-cell lymphoma. March 21, 2023. Accessed March 22, 2023.